<code id='2748BBF330'></code><style id='2748BBF330'></style>
    • <acronym id='2748BBF330'></acronym>
      <center id='2748BBF330'><center id='2748BBF330'><tfoot id='2748BBF330'></tfoot></center><abbr id='2748BBF330'><dir id='2748BBF330'><tfoot id='2748BBF330'></tfoot><noframes id='2748BBF330'>

    • <optgroup id='2748BBF330'><strike id='2748BBF330'><sup id='2748BBF330'></sup></strike><code id='2748BBF330'></code></optgroup>
        1. <b id='2748BBF330'><label id='2748BBF330'><select id='2748BBF330'><dt id='2748BBF330'><span id='2748BBF330'></span></dt></select></label></b><u id='2748BBF330'></u>
          <i id='2748BBF330'><strike id='2748BBF330'><tt id='2748BBF330'><pre id='2748BBF330'></pre></tt></strike></i>

          
          WSS
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge